Supernus Pharmaceuticals (SUPN) Other Operating Expenses (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Other Operating Expenses data on file, last reported at $65.3 million in Q4 2025.

• On a quarterly basis, Other Operating Expenses rose 46.07% year-over-year to $65.3 million in Q4 2025; TTM through Mar 2026 was $146.2 million, a 7.23% decrease from a year earlier, with the FY2025 full-year figure at $189.4 million, up 26.48% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $65.3 million, up from $43.3 million in the prior quarter.
• Over the last five years, Other Operating Expenses for SUPN reached as high as $65.3 million in Q4 2025 and fell as low as $22.2 million in Q2 2021.
• Historically, Other Operating Expenses has averaged $40.6 million across 5 years, with a median of $41.3 million in 2021.
• Across the five-year window, Other Operating Expenses soared 662.26% in 2021 and slipped 26.34% in 2024, its largest moves.
• Year by year, Other Operating Expenses stood at $30.1 million in 2021, then soared by 36.86% to $41.2 million in 2022, then surged by 47.11% to $60.7 million in 2023, then decreased by 26.34% to $44.7 million in 2024, then jumped by 46.07% to $65.3 million in 2025.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $65.3 million in Q4 2025, $43.3 million in Q3 2025, and $37.6 million in Q2 2025.